Show simple item record

dc.contributor.advisorMitchell, Shaneice
dc.creatorAsmelash, Yerdanos
dc.date.accessioned2017-09-19T22:14:28Z
dc.date.available2017-09-19T22:14:28Z
dc.date.issued2017-09-14
dc.identifier.urihttp://hdl.handle.net/1811/81128
dc.description.abstractAcute Myeloid Leukemia (AML) is a cancer characterized by abnormal cell growth of immature myeloid cells. Currently, AML is treatable in about 35 to 40% of adult patients who are 60 years or younger, and less favorable in patients who are 60 years or older where rates are 5 to 15%. In addition, most patients have multiple malignant clones of leukemic stem cells, each differing in their responses to treatment. However, studies have shown that inhibition of the enzyme nicotinamide phosphoribosyltransferase (NAMPT) is a possible avenue for treatment of AML. NAMPT is responsible for the production of NAD+, a key metabolite needed for various cellular functions. By inhibiting NAMPT, NAD+ production is expected to decrease, thus resulting in cell death. The purpose of this study is to evaluate the ability of KPT-9274, a novel NAMPT inhibitor, to eradicate leukemic colonies in AML. To assess the ability of KPT-9274 to decrease colony formation, three AML leukemic patient cells were treated with KPT-9274. Cells were plated and incubated on a 6-well cell culture plate, along with a control group in a semi-solid medium. After two weeks, leukemic cell colonies were counted using an inverted light microscope. The cells were washed with 20% RPMI media, underwent a dilution process to achieve a desired amount of cells, and then re-plated to assess self-renewal capacity. Colony formation decreased in the three AML leukemic patient cells by 39.7 to 75.9%. These results are consistent with previous findings that support the drug’s potential to decrease NAD+ production, leading to decrease in colony formation. Self-renewal capacity of the three patients is currently being assessed. Overall, this study provides evidence that the NAMPT inhibitor, KPT-9274, is able to eradicate malignant clones found in AML patients that may lead to patient relapse.en_US
dc.description.sponsorshipR35 CA197734en_US
dc.description.sponsorshipPelotonia Idea Awarden_US
dc.description.sponsorshipD Warren Brown Foundationen_US
dc.description.sponsorshipKaryopharm Therapeuticsen_US
dc.language.isoenen_US
dc.relation.ispartofseries2017 Fall Undergraduate Research Student Poster Forum. 11then_US
dc.subjectNAMPT inhibitor Acute Myeloid Leukemiaen_US
dc.subjectKPT-9274 alternative treatmenten_US
dc.titleNAMPT inhibitor KPT-9274 as an alternative treatment for Acute Myeloid Leukemiaen_US
dc.typePresentationen_US
dc.type.genrePosteren_US
dc.description.academicmajorAcademic Major: Biologyen_US


Files in this item

Thumbnail

Items in Knowledge Bank are protected by copyright, with all rights reserved, unless otherwise indicated.

This item appears in the following Collection(s)

Show simple item record